메뉴 건너뛰기




Volumn 92, Issue 2, 2014, Pages 137-146

Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: A single-center analysis of 115 patients

Author keywords

Allogeneic hematopoietic cell transplantation; Graft versus host disease; Graft versus leukemia effect; Myelodysplastic syndrome

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY;

EID: 84892676439     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12214     Document Type: Article
Times cited : (15)

References (40)
  • 1
    • 47249150213 scopus 로고    scopus 로고
    • Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
    • Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
    • (2008) Blood , vol.112 , pp. 45-52
    • Rollison, D.E.1    Howlader, N.2    Smith, M.T.3    Strom, S.S.4    Merritt, W.D.5    Ries, L.A.6    Edwards, B.K.7    List, A.F.8
  • 2
    • 3242774628 scopus 로고    scopus 로고
    • Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
    • de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004;104:865-72.
    • (2004) Blood , vol.104 , pp. 865-872
    • de Lima, M.1    Anagnostopoulos, A.2    Munsell, M.3
  • 3
    • 33750205692 scopus 로고    scopus 로고
    • Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome
    • Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, Ritz J, Antin JH, Soiffer RJ. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006;12:1047-55.
    • (2006) Biol Blood Marrow Transplant , vol.12 , pp. 1047-1055
    • Alyea, E.P.1    Kim, H.T.2    Ho, V.3    Cutler, C.4    DeAngelo, D.J.5    Stone, R.6    Ritz, J.7    Antin, J.H.8    Soiffer, R.J.9
  • 4
    • 0030925301 scopus 로고    scopus 로고
    • Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy
    • Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
    • (1997) Blood , vol.89 , pp. 4531-4536
    • Giralt, S.1    Estey, E.2    Albitar, M.3
  • 5
    • 0032006125 scopus 로고    scopus 로고
    • Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
    • Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
    • (1998) Blood , vol.91 , pp. 756-763
    • Slavin, S.1    Nagler, A.2    Naparstek, E.3
  • 6
    • 33746661102 scopus 로고    scopus 로고
    • Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes
    • Martino R, Iacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836-46.
    • (2006) Blood , vol.108 , pp. 836-846
    • Martino, R.1    Iacobelli, S.2    Brand, R.3
  • 8
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
    • (1997) Blood , vol.89 , pp. 2079-2088
    • Greenberg, P.1    Cox, C.2    LeBeau, M.M.3
  • 10
    • 0035203456 scopus 로고    scopus 로고
    • Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis
    • Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001;28:909-15.
    • (2001) Bone Marrow Transplant , vol.28 , pp. 909-915
    • Klein, J.P.1    Rizzo, J.D.2    Zhang, M.J.3    Keiding, N.4
  • 11
    • 0035663624 scopus 로고    scopus 로고
    • Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling
    • Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: regression modeling. Bone Marrow Transplant 2001;28:1001-11.
    • (2001) Bone Marrow Transplant , vol.28 , pp. 1001-1011
    • Klein, J.P.1    Rizzo, J.D.2    Zhang, M.J.3    Keiding, N.4
  • 12
    • 20144362213 scopus 로고    scopus 로고
    • Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning
    • Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005;23: 1993-2003.
    • (2005) J Clin Oncol , vol.23
    • Baron, F.1    Maris, M.B.2    Sandmaier, B.M.3
  • 14
    • 0025100777 scopus 로고
    • Graft-versus-leukemia reactions after bone marrow transplantation
    • Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-62.
    • (1990) Blood , vol.75 , pp. 555-562
    • Horowitz, M.M.1    Gale, R.P.2    Sondel, P.M.3
  • 15
    • 0024566585 scopus 로고
    • Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
    • Sullivan KM, Weiden PL, Storb R, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-8.
    • (1989) Blood , vol.73 , pp. 1720-1728
    • Sullivan, K.M.1    Weiden, P.L.2    Storb, R.3
  • 16
    • 39149133203 scopus 로고    scopus 로고
    • Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival
    • Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008;26:577-84.
    • (2008) J Clin Oncol , vol.26 , pp. 577-584
    • Valcarcel, D.1    Martino, R.2    Caballero, D.3
  • 17
    • 0033971243 scopus 로고    scopus 로고
    • Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle
    • Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000;18:537-46.
    • (2000) J Clin Oncol , vol.18 , pp. 537-546
    • Blaise, D.1    Kuentz, M.2    Fortanier, C.3
  • 18
    • 0035905908 scopus 로고    scopus 로고
    • Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
    • Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001;344:175-81.
    • (2001) N Engl J Med , vol.344 , pp. 175-181
    • Bensinger, W.I.1    Martin, P.J.2    Storer, B.3
  • 19
    • 0036720739 scopus 로고    scopus 로고
    • A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies
    • Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002;100:1525-31.
    • (2002) Blood , vol.100 , pp. 1525-1531
    • Couban, S.1    Simpson, D.R.2    Barnett, M.J.3
  • 20
    • 69249193742 scopus 로고    scopus 로고
    • Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
    • Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10:855-64.
    • (2009) Lancet Oncol , vol.10 , pp. 855-864
    • Finke, J.1    Bethge, W.A.2    Schmoor, C.3
  • 21
    • 0035892107 scopus 로고    scopus 로고
    • Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)
    • Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98:2942-7.
    • (2001) Blood , vol.98 , pp. 2942-2947
    • Bacigalupo, A.1    Lamparelli, T.2    Bruzzi, P.3
  • 22
    • 79959456118 scopus 로고    scopus 로고
    • Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius
    • Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011;117: 6375-82.
    • (2011) Blood , vol.117
    • Socie, G.1    Schmoor, C.2    Bethge, W.A.3
  • 23
    • 62849104641 scopus 로고    scopus 로고
    • Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009;10:223-32.
    • (2009) Lancet Oncol , vol.10 , pp. 223-232
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 24
    • 77449149373 scopus 로고    scopus 로고
    • Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
    • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010;28:562-9.
    • (2010) J Clin Oncol , vol.28 , pp. 562-569
    • Fenaux, P.1    Mufti, G.J.2    Hellstrom-Lindberg, E.3
  • 25
    • 78649601394 scopus 로고    scopus 로고
    • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study
    • de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K, Braun TM, Nguyen HQ, Champlin R, Garcia-Manero G. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010;116:5420-31.
    • (2010) Cancer , vol.116 , pp. 5420-5431
    • de Lima, M.1    Giralt, S.2    Thall, P.F.3    de Padua Silva, L.4    Jones, R.B.5    Komanduri, K.6    Braun, T.M.7    Nguyen, H.Q.8    Champlin, R.9    Garcia-Manero, G.10
  • 26
    • 84857999119 scopus 로고    scopus 로고
    • Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
    • Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012;26:381-9.
    • (2012) Leukemia , vol.26 , pp. 381-389
    • Platzbecker, U.1    Wermke, M.2    Radke, J.3
  • 28
    • 0021160287 scopus 로고
    • 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias
    • Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 1984;64:922-9.
    • (1984) Blood , vol.64 , pp. 922-929
    • Pinto, A.1    Attadia, V.2    Fusco, A.3    Ferrara, F.4    Spada, O.A.5    Di Fiore, P.P.6
  • 29
    • 0021133490 scopus 로고
    • Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine
    • Pinto A, Maio M, Attadia V, Zappacosta S, Cimino R. Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2′-deoxycytidine. Lancet 1984;2:867-8.
    • (1984) Lancet , vol.2 , pp. 867-868
    • Pinto, A.1    Maio, M.2    Attadia, V.3    Zappacosta, S.4    Cimino, R.5
  • 30
    • 0022404250 scopus 로고
    • Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine
    • Momparler RL, Bouchard J, Samson J. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine. Leuk Res 1985;9:1361-6.
    • (1985) Leuk Res , vol.9 , pp. 1361-1366
    • Momparler, R.L.1    Bouchard, J.2    Samson, J.3
  • 31
    • 2342451871 scopus 로고    scopus 로고
    • Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate
    • Kanda Y, Izutsu K, Hirai H, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia 2004;18:1013-9.
    • (2004) Leukemia , vol.18 , pp. 1013-1019
    • Kanda, Y.1    Izutsu, K.2    Hirai, H.3
  • 32
    • 31444444950 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity
    • Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006;20:322-8.
    • (2006) Leukemia , vol.20 , pp. 322-328
    • Shimoni, A.1    Hardan, I.2    Shem-Tov, N.3    Yeshurun, M.4    Yerushalmi, R.5    Avigdor, A.6    Ben-Bassat, I.7    Nagler, A.8
  • 33
    • 75749124680 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia
    • Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010;28:405-11.
    • (2010) J Clin Oncol , vol.28 , pp. 405-411
    • Lim, Z.1    Brand, R.2    Martino, R.3
  • 34
    • 79953708226 scopus 로고    scopus 로고
    • Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation
    • Khabori MA, El-Emary M, Xu W, Guyatt G, Galal A, Kuruvilla J, Lipton J, Messner H, Gupta V. Impact of intensity of conditioning therapy in patients aged 40-60 years with AML/myelodysplastic syndrome undergoing allogeneic transplantation. Bone Marrow Transplant 2011;46:516-22.
    • (2011) Bone Marrow Transplant , vol.46 , pp. 516-522
    • Khabori, M.A.1    El-Emary, M.2    Xu, W.3    Guyatt, G.4    Galal, A.5    Kuruvilla, J.6    Lipton, J.7    Messner, H.8    Gupta, V.9
  • 35
    • 33644967374 scopus 로고    scopus 로고
    • Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
    • Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG, Chauncey TR, Storb R, Deeg HJ. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006;20:128-35.
    • (2006) Leukemia , vol.20 , pp. 128-135
    • Scott, B.L.1    Sandmaier, B.M.2    Storer, B.3    Maris, M.B.4    Sorror, M.L.5    Maloney, D.G.6    Chauncey, T.R.7    Storb, R.8    Deeg, H.J.9
  • 37
    • 34948869819 scopus 로고    scopus 로고
    • Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation
    • Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-54.
    • (2007) J Clin Oncol , vol.25 , pp. 4246-4254
    • Sorror, M.L.1    Sandmaier, B.M.2    Storer, B.E.3    Maris, M.B.4    Baron, F.5    Maloney, D.G.6    Scott, B.L.7    Deeg, H.J.8    Appelbaum, F.R.9    Storb, R.10
  • 38
    • 11244278531 scopus 로고    scopus 로고
    • Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome
    • Scott BL, Storer B, Loken MR, Storb R, Appelbaum FR, Deeg HJ. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005;11:65-73.
    • (2005) Biol Blood Marrow Transplant , vol.11 , pp. 65-73
    • Scott, B.L.1    Storer, B.2    Loken, M.R.3    Storb, R.4    Appelbaum, F.R.5    Deeg, H.J.6
  • 39
    • 58149196171 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden
    • Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Biol Blood Marrow Transplant 2009;15:30-8.
    • (2009) Biol Blood Marrow Transplant , vol.15 , pp. 30-38
    • Warlick, E.D.1    Cioc, A.2    Defor, T.3    Dolan, M.4    Weisdorf, D.5
  • 40
    • 20144375580 scopus 로고    scopus 로고
    • Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome
    • Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005;19:396-401.
    • (2005) Leukemia , vol.19 , pp. 396-401
    • Nakai, K.1    Kanda, Y.2    Fukuhara, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.